Navigation Links
Sigma® Life Science Launches CompoZr® Targeted Integration Kit - mRosa26 for the Mouse Genome

ST. LOUIS, July 19, 2011 /PRNewswire/ -- Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich Corporation (Nasdaq: SIAL) today announced the launch of CompoZr Targeted Integration Kit – mRosa26, which can precisely and rapidly integrate transgenes into the mouse genome at the Rosa26 safe harbor locus. This kit follows the introduction of the CompoZr Targeted Integration Kit – AAVS1, for transgene integration in the human genome. For additional information on both kits, visit

Traditional transgenic approaches rely on random integration of a transgene. This low efficiency approach results in multiple random integration events at off-target insertion sites, and often requires the use of antibiotic selection strategies. In addition, the integration event can involve multiple copies of the transgene. Using the CompoZr ZFN technology, a single copy of a transgene can be targeted and inserted in the Rosa26 locus, which is a well-defined safe harbor site in the mouse genome. Sigma's CompoZr Targeted Integration Kits use zinc finger nucleases (ZFNs) for precise and heritable gene knockin at the target locus (Rosa26 or AAVS1). Both Human and Mouse kits are supplied with the necessary ZFNs and donor plasmid to successfully perform transgene integration by ZFN-assisted homologous recombination, reducing the timescale and complexity of engineering transgenic mouse and human cell lines.

"ZFN mediated transgene integration using Sigma's CompoZr Targeted Integration Kit – mRosa26 represents the most efficient method for targeted transgene integration at the highly characterized Rosa26 locus of the mouse genome," said Dr. Supriya Shivakumar, Global Commercial Marketing Manager for Functional Genomics at Sigma Life Science. "This latest release is part of Sigma's ongoing objective to increase the research community's access to advanced genomic engineering strategies by offering innovative, easy-to-use products based on our proprietary zinc finger nuclease technology."

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "precisely and rapidly," "expected," "represents the most efficient," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that CompoZr Targeted Integration Kit – mRosa26 will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with that CompoZr Targeted Integration Kit – mRosa26 could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range of critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company committed to Enabling Science to Improve the Quality of Life. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 40 countries and has 8,000 employees providing excellent service worldwide. For more information about Sigma-Aldrich, please visit its award-winning Web site at

Sigma-Aldrich, Sigma and CompoZr are registered trademarks of Sigma-Aldrich Co LLC.

SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Magellan Biosciences Sells TREK Microbiology Business to Thermo Fisher Scientific
2. Caliper Life Sciences to Ring The NASDAQ Stock Market Opening Bell on Tuesday, July 19
3. Coronado Biosciences Files to Become a Public Reporting Company
4. SARcode Bioscience Completes $44 Million Series B Financing
5. Convergen LifeSciences Announces Patent Award
6. Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services
7. USANA Health Sciences Is Now an FDA-Registered Facility
9. Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED
10. Coronado Biosciences Closes $25.8M in Series C Financing
11. Tibotec Pharmaceuticals Announces Agreement With Gilead Sciences to Develop and Commercialize a New Fixed-Dose Combination of PREZISTA® and Cobicistat
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was ... inventor from Hillside, N.J. "Many people catch diseases simply from sitting on such ... always be protected from germs." , He developed the patent-pending QUDRATECS to eliminate ...
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... ... 27, 2015 , ... The moment you stop improving is ... fulfilling the needs of advisers and clients but going above and beyond to ... customer service. However, there's always room for improvement, which is why the entire ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
Breaking Medicine News(10 mins):